A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors

A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors

Abstract Background Based on preclinical data showing addition of CDK4/6 inhibitors to gemcitabine was synergistic, ribociclib was evaluated in combination with gemcitabine to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT). Methods In this single arm multicohort phase...

Full description

Saved in:
Bibliographic Details
Main Authors: Aurora Norman, Mahesh Seetharam, Jacob Allred, Jianping Kong, Mateusz Opyrchal, Wen Wee Ma, Yanyan Lou, Grace K. Dy, Amit Mahipal, S. John Weroha, Andrea E. Wahner Hendrickson, Joel M. Reid, Alex A. Adjei
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:BJC Reports
Online Access:https://doi.org/10.1038/s44276-024-00107-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s44276-024-00107-0

Similar Items